Acasti Pharma Inc. (ACST)’s Financial Results Comparing With Sarepta Therapeutics Inc. (NASDAQ:SRPT)

This is therefore a comparing of the institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation in Acasti Pharma Inc. (NASDAQ:ACST) and Sarepta Therapeutics Inc. (NASDAQ:SRPT). The two are both Biotechnology companies that compete with one another.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Acasti Pharma Inc. N/A 0.00 N/A -1.22 0.00
Sarepta Therapeutics Inc. 323.44M 30.82 403.20M -5.42 0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Acasti Pharma Inc. and Sarepta Therapeutics Inc.

Profitability

Table 2 shows the net margins, return on assets and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
Acasti Pharma Inc. 0.00% 0% 0%
Sarepta Therapeutics Inc. -124.66% 0% 0%

Analyst Ratings

Acasti Pharma Inc. and Sarepta Therapeutics Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Acasti Pharma Inc. 0 0 0 0.00
Sarepta Therapeutics Inc. 0 0 14 3.00

Competitively Sarepta Therapeutics Inc. has an average target price of $205.31, with potential upside of 52.75%.

Institutional & Insider Ownership

Roughly 4.02% of Acasti Pharma Inc. shares are held by institutional investors while 93.5% of Sarepta Therapeutics Inc. are owned by institutional investors. Insiders held roughly 13.28% of Acasti Pharma Inc.’s shares. On the other hand, insiders held about 4.5% of Sarepta Therapeutics Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Acasti Pharma Inc. 6.12% -10.53% -3.39% -14.14% 27.86% 2.18%
Sarepta Therapeutics Inc. 4.1% -0.48% -11.54% -5% 28.02% 9.22%

For the past year Acasti Pharma Inc.’s stock price has smaller growth than Sarepta Therapeutics Inc.

Summary

Sarepta Therapeutics Inc. beats Acasti Pharma Inc. on 5 of the 8 factors.

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. The company's lead product candidate is CaPre, an omega-3 phospholipid for the treatment of hypertriglyceridemia. Acasti Pharma Inc. was incorporated in 2002 and is based in Laval, Canada.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD. The company has a strategic alliance with Nationwide Children's Hospital for the advancement of microdystrophin gene therapy program under the research and option agreement, as well as Galgt2 gene therapy program under the license agreement; Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD under the research collaboration agreement; and CharleyÂ’s Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies under the research agreement. It also has a license agreement with the University of Western Australia for treatment of DMD by inducing the skipping of certain exons; collaboration and license agreement with Summit (Oxford) Ltd. for the development of ezutromid, an utrophin modulator which is in phase II clinical trials for the treatment of DMD; and a gene therapy research collaboration with Genethon to develop treatments for Duchenne muscular dystrophy. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.